Aims: The aim of this research is to explore the presence of multidrug-resistance (MDR) Acinetobacter baumannii strains isolated from hospitalized patients in a tertiary-care center, Subang Jaya, Selangor, Malaysia and to compare their genotypic and phenotypic characteristics. Methodology and results: Clonal relationships were determined by multilocus sequence typing (MLST) and biofilm forming ability was evaluated by using 2, 3 - bis (2 - methoxy - 4 - nitro - 5-sulfophenyl) - 5 - [(phenylamino) carbonyl] - 2H-tetrazolium hydroxide (XTT) reduction assay in microplates and Congo red agar method (CRA). Four virulence genes coding for A. baumannii pilus usher-chaperone assembly protein, csuE gene; outer membrane protein, ompA gene; biofilm poly-β-1, 6-Nacetylglucosamine (PNAG) synthesis protein, pgaA gene; and acinetobactin-mediated iron acquisition protein, bauA gene were searched for in a collection of strains. Antimicrobial resistance against 11 antibiotics were studied by broth microdilution method. Seventeen A. baumannii clinical strains were isolated and MLST showed that the strains belonged to 5 distinct sequence types (STs), namely, ST-6, ST-265, ST-324, ST-325 and ST-432. Fiftythree percent of the strains were resistant to 4 or more antibiotics. Twelve strains produced biofilm and out of them, 4 were strong biofilm producer, besides, these strong biofilm producers were MDR strains and belongs to ST-6. In addition, all strains were ompA positive, biofilm producing strains were csuE and pgaA positive and only strong biofilm producing strains were bauA positive. Conclusion, significance and impact study: Our study demonstrates that the ST-6 strains in Malaysia could represent MDR, capable of forming strong biofilm and possess csuE, ompA, pgaA and bauA genes, virulence characteristics that probably help the bacteria to persist and cause infection.
Acinetobacter baumannii

No abstract available.
Acinetobacter baumannii* ; Acinetobacter* ; Pneumonia*

We collected 76 clinical isolates of Acinetobacter baumannii (amikacin MIC by Vitek 2 AST-N055 card: < or =2microgram/mL, 11 isolates; 4microgram/mL, 19 isolates; 8microgram/ mL, 17 isolates; 16microgram/mL, 27 isolates; and > or =64microgram/ mL, 2 isolates) from a university hospital and evaluated the Vitek 2 AST-N055 card vs the broth microdilution as a reference method for testing susceptibility to amikacin. Vitek 2 AST-N055 card yielded very major errors in 15 isolates (19.7%) and minor errors in 26 isolates (34.2%). Of the 15 isolates shown very major errors, 14 had Vitek 2 MICs ranging from 8 to 16microgram/mL. The results of our study suggest strongly that it is unreliable to test the amikacin susceptibility by Vitek 2 AST-N055 card of A. baumannii with the Vitek 2 MICs ranging from 8 to 16microgram/mL. In those cases, another susceptibility test, such as broth microdilution (BMD), should be performed to confirm the results.
Acinetobacter ; Acinetobacter baumannii ; Amikacin

No abstract available.
Acinetobacter baumannii* ; Acinetobacter* ; Hospitals, General* ; Imipenem* ; Korea*

No abstract available.
Acinetobacter baumannii ; Acinetobacter ; Colistin ; Solanum tuberosum

No abstract available.
Acinetobacter baumannii* ; Intensive Care Units*

Background: Intraventricular antimicrobial therapy (IVT), defined as the direct installation of antimicrobial agents into the lateral ventricles has been utilized as the last therapeutic option for the treatment of multidrug-resistant ventriculitis. The aim of this case series is to report our institution’s experience with IVT in pediatric patients with ventriculitis. Material and Methods: Retrospective chart review was done. The demographic data, cerebrospinal fluid (CSF) culture isolates, treatment regimens, and clinical outcomes of these patients were collected and described. Results: Between 2016 to 2018, seven (7) pediatric patients diagnosed with ventriculitis caused by multidrug-resistant organisms underwent intraventricular antimicrobial therapy in combination with intravenous therapy. The median age was 1 year (range 1 month to 17 years old, mean: 4.4 years). Fifty-seven (57) percent of the patients were females. The isolated pathogens were Acinetobacter baumannii MDRO (n = 3), Klebsiella pneumoniae MDRO (n = 2), Methicillin-resistant Staphylococcus aureus (n = 1), and Methicillin-resistant Staphylococcus epidermidis (n = 2).One patient had mixed isolates on CSF culture (Acinetobacter baumannii and MRSE). The antimicrobial agents for IVT used were colistin (n = 4), vancomycin (n = 2), and gentamicin (n = 1). The mean time to initiation of intraventricular therapy from the diagnosis of ventriculitis was 19 days. The mean duration of IVT therapy was 15 days. The survival rate was 57%. Conclusion Ventriculitis caused by drug-resistant organisms is an emerging concern. Optimal therapy is not yet established and experience with IVT is limited. This series showed that there were no adverse effects related to IVT thus it may be considered an option for MDRO ventriculitis. Gram negative organisms are more common causes of ventriculitis in our institution.
Acinetobacter baumannii ; Methicillin-Resistant Staphylococcus aureus

BACKGROUND: The glucose -acidifying genomic species 1, 2, 3 and 13 of the genus Acinetobacter are highly related genetically and may be difficult to differentiate by phenotypic identification schemes using biochemical tests. The aim of this study was to explore the brief restriction enzyme profiles of amplified ribosomal DNA restriction analysis (ARDRA) to identify medically important species of Acinetobacter. Using ARDRA analysis, we evaluated the ID 32 GN system (bioMerieux, Lyon, France) for the identification of A. baumannii (genospecies 2). METHODS: A collection of 78 A. baumannii stains initially identified by the ID 32 GN system was used to determine its accuracy by ARDRA analysis. ARDRA was performed with 10 different restriction enzymes, AluI (AGCT), CfoI (GCGC), HaeIII (GGCC), HinfI (GANTC), MboI (GATC), MspI (CCGG), NciI (CCGG), RsaI (GTAC), ScrFI (CCNGG) and TaqI (TCGA). RESULTS: The combination of restriction patterns obtained with respective enzymes AluI, CfoI and MboI allowed for the discriminatory value for the identification of medically important genospecies such as genospecies 2 (A. baumannii), 3 and 13. By comparing ARDRA results of the 78 strains previously identified by ID 32 GN system, we found the correlation rate between the two systems to be 88.5% (69/78). Nine strains were identified as Acinetobacter genospecies 13 by ARDRA. CONCLUSIONS: This result suggests that the ID 32 GN system may have difficulty in discriminating A. baumannii from genospecies 13. This revised ARDRA method gives a relatively rapid and definitive result for the identification of medically important genospecies of Acinetobacter.
Acinetobacter ; Acinetobacter baumannii* ; Coloring Agents ; DNA, Ribosomal* ; Glucose

Acinetobacter species is a non-fermentative aerobic gram-negative coccobacillus that is an important pathogen found in nosocomial infections. Recently, multi-drug resistant Acinetobacter baumannii (MDR-AB) infections have been increasing and pose a serious problem. Most such infections present as bacteremia, pneumonia, or a wound infection; however, CNS infections are very rare. We herein present a case of ventriculitis caused by MDR-AB in a 37-year old man after a neurosurgical intervention. The patient was successfully treated with intrathecal colistimethate.
Acinetobacter ; Acinetobacter baumannii ; Bacteremia ; Colistin ; Cross Infection ; Humans ; Pneumonia

Acinetobacter species is a non-fermentative aerobic gram-negative coccobacillus that is an important pathogen found in nosocomial infections. Recently, multi-drug resistant Acinetobacter baumannii (MDR-AB) infections have been increasing and pose a serious problem. Most such infections present as bacteremia, pneumonia, or a wound infection; however, CNS infections are very rare. We herein present a case of ventriculitis caused by MDR-AB in a 37-year old man after a neurosurgical intervention. The patient was successfully treated with intrathecal colistimethate.
Acinetobacter ; Acinetobacter baumannii ; Bacteremia ; Colistin ; Cross Infection ; Humans ; Pneumonia